賽倫生物(688163.SH):部分股東擬合計增持380萬元-630萬元公司股份
格隆匯2月23日丨賽倫生物(688163.SH)公佈,公司實際控制人之一、董事、總經理範鐵炯先生,及副總經理、董事會祕書成瓊女士,副總經理彭良俊先生,財務總監李紹陽先生(以下簡稱“增持主體”)基於對公司未來發展的信心和對公司長期投資價值的認可,同時為增強投資者信心,維護公司全體股東利益,計劃自2024年2月26日起6個月內,通過上海證券交易所繫統允許的方式(包括但不限於集中競價和大宗交易等)增持公司股份,本次合計增持金額不低於人民幣380萬元,且不超過人民幣630萬元。本次增持計劃不設置增持股份價格區間,增持主體將根據公司股票的價格波動情況及資本市場整體趨勢擇機實施增持計劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.